The Lancet Oncology in conversation with

The Lancet Group

Head and Neck Cancer

Diffuse Intracranial Glioma

Global Cancer Surgery

Clinical Trials

Human Papillomavirus

Radiotherapy

Standardization In Medicine

Extranodal Extension

Valometastat

Immunotherapy

Multidisciplinary Workforce

Surgical Oncology

Cancer Research

Cancer Care

Tissue Sampling

Glioma Treatment Approaches

Pandemic Impact On Healthcare

Cervical Cancer

Human Papillomavirus Vaccine

Stereotactic Body Radiotherapy

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxici... more

7 ratings

Publishes	Monthly	Episodes	214	Founded	5 years ago
Number of Listeners		Categories	Health & FitnessScienceLife SciencesMedicine

Listen to this Podcast

Guests Hosts Charts Talking Points

Latest Episodes

Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission

Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.

Click here to read the full Commission: The human crisis ... more

2 Nov 2025 • 10 min

Matthias Preusser on the phase 2 TUXEDO-3 trial

Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breas... more

27 Oct 2025 • 17 min

Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to ... more

29 Sep 2025 • 12 min

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Kat Gourd, Acting Deputy Editor of The Lancet Oncology, is joined by Dr Linda Bi, Dr Ruchit Patel, Dr Chloe Gui, Dr Farshad Nassiri, and Dr Matija Snuderl, from institutions in the USA and Canada, to discuss two exciting papers on TERT expression and... more

2 Sep 2025 • 14 min

Key Facts

Accepts Guests

Contact Information

Podcast Host

Number of Listeners

Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

JAMA Editors' SummaryJAMA Network

NEJM This WeekNEJM Group

Journal of Clinical Oncology (JCO) PodcastAmerican Society of Clinical Oncology (ASCO)

JAMA Clinical ReviewsJAMA Network

ASCO GuidelinesAmerican Society of Clinical Oncology (ASCO)

Recent Guests

Dr. Matthias Preusser

Professor of Medical Oncology and Head of the Division of Oncology at the Medical University of Vienna, Austria

Medical University of Vienna, Austria

Episode: Matthias Preusser on the phase 2 TUXEDO-3 trial

Dr. Andrea Necchi

Associate Professor at the Vita-Salute San Raffaele University and Director of Genitourinary Medical Oncology at the San Raffaele Hospital in Milan, Italy

Vita-Salute San Raffaele University, San Raffaele Hospital

Episode: Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer

Dr. Jinming Li

Doctor from the Department of Colorectal Surgery, Fudan University, Shanghai Cancer Centre

Fudan University, Shanghai Cancer Centre

Episode: Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer

Professor Richard Bryant

Professor from the University of Oxford, discussing prostate cancer biopsy approaches

University of Oxford

Episode: Richard Bryant on transperineal vs transrectal biopsy for prostate cancer

Dr. Ariana Znaor

Representative from the International Agency for Research on Cancer

International Agency for Research on Cancer

Episode: Ariana Znaor on cancer surveillance in the Eastern Mediterranean region

Yannick Romero

Doctor from the Union for International Cancer Control

Union for International Cancer Control

Episode: Yannick Romero on the changing landscape of national cancer control plans

Dr. Steven Horwitz

Co-author of papers on valometastat and its role in treating relapsed or refractory T-cell lymphoma

Memorial Sloan Kettering Cancer Center

Episode: Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

Zachary Zumsteg

Associate Professor at Cedars-Sinai Medical Center

Cedars-Sinai Medical Center

Episode: Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

Professor May Abdel-Wahab

Director of the Division of Human Health, Department of Nuclear Science and Applications, at the International Atomic Energy Agency

International Atomic Energy Agency

Episode: May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

Hosts

Kat Gourd

Acting Deputy Editor of The Lancet Oncology

Dr. Smriti Patodia

Senior Editor

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Apple Podcasts	#221	Australia/Health & Fitness/Medicine
Apple Podcasts	#97	Japan/Health & Fitness/Medicine
Apple Podcasts	#119	Singapore/Health & Fitness/Medicine
Apple Podcasts	#187	Hong Kong/Health & Fitness/Medicine
Apple Podcasts	#188	Netherlands/Health & Fitness/Medicine
Apple Podcasts	#214	India/Health & Fitness/Medicine
Apple Podcasts	#249	Austria/Health & Fitness/Medicine

Talking Points

Recent interactions between the hosts and their guests.

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Q: Finally, do you foresee your findings changing the current WHO classification of meningiomas?

While the findings are significant, any changes to the WHO classification will require broad consensus among clinicians and further prospective studies to validate findings.

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Q: In view of the fact that most meningiomas are classified as benign non-cancerous tumors, why is it so important to profile these tumors so thoroughly and to ensure that they are classified accurately?

Accurate grading and profiling help guide treatment decisions, especially in cases where benign tumors show more aggressive behaviors that necessitate different management strategies.

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Q: Was there anything that surprised you in your results?

They found a higher prevalence of TERT expression versus TERT promoter mutations, with significant implications for understanding tumor behavior and classifications.

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Q: Could you please summarize the main findings of your two studies?

The studies revealed that up to one-third of meningiomas expressed TERT, linked to poorer outcomes, and that TERT expression was a more significant biomarker than TERT promoter mutations, which did not independently predict outcomes.

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

Q: Firstly, why did you decide to undertake these two research studies on TERT expression and TERT promoter mutations in meningiomas? Why were they needed?

The researchers observed inconsistencies in the prognostic implications of TERT mutations versus expression in meningiomas, prompting them to study the impact of these factors on patient outcomes and tumor classification.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The Lancet Oncology in conversation with

What is The Lancet Oncology in conversation with about and what kind of topics does it cover?

A series of conversations with leading researchers and medical professionals explore a diverse range of oncology topics, highlighting recent advancements in cancer research and treatment methodologies. Discussions cover significant issues, including genomic mutations in cancer patients, new therapies and drugs, cancer treatment protocols, and the challenges of cancer control on a global scale. The episodes delve into specifics such as prostate biopsy techniques, immunotherapy applications, and the effectiveness of various clinical trials, offering listeners a comprehensive understanding of contemporary oncology developments and their implications for patient care.

Where can I find podcast stats for The Lancet Oncology in conversation with?

Rephonic provides a wide range of podcast stats for The Lancet Oncology in conversation with. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The Lancet Oncology in conversation with and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The Lancet Oncology in conversation with get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for The Lancet Oncology in conversation with, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The Lancet Oncology in conversation with?

Rephonic provides comprehensive predictive audience data for The Lancet Oncology in conversation with, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The Lancet Oncology in conversation with have?

To see how many followers or subscribers The Lancet Oncology in conversation with has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The Lancet Oncology in conversation with?

These podcasts share a similar audience with The Lancet Oncology in conversation with:

1. JAMA Editors' Summary
2. NEJM This Week
3. Journal of Clinical Oncology (JCO) Podcast
4. JAMA Clinical Reviews
5. ASCO Guidelines

How many episodes of The Lancet Oncology in conversation with are there?

The Lancet Oncology in conversation with launched 5 years ago and published 214 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The Lancet Oncology in conversation with?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The Lancet Oncology in conversation with?

Rephonic pulls ratings and reviews for The Lancet Oncology in conversation with from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The Lancet Oncology in conversation with?

Rephonic provides full transcripts for episodes of The Lancet Oncology in conversation with. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The Lancet Oncology in conversation with?

Recent guests on The Lancet Oncology in conversation with include:

1. Dr. Matthias Preusser
2. Dr. Andrea Necchi
3. Dr. Jinming Li
4. Professor Richard Bryant
5. Dr. Ariana Znaor
6. Yannick Romero
7. Dr. Steven Horwitz
8. Zachary Zumsteg

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.

Try it free for 7 days